Recombinant Dna Technique Included In Method Of Making A Protein Or Polypeptide Patents (Class 435/69.1)
  • Patent number: 9765321
    Abstract: Novel promoters which are derived from P. pastoris pastoris which are inducible or repressible under specific growth conditions are provided. These promoters are useful for regulating the expression of a desired structural gene, e.g., a mammalian polypeptide. Particularly preferred is the use of these novel promoters to regulate gene expression in polyploidal yeast such as diploidal P. pastoris produced by mating or spheroplast fusion.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: September 19, 2017
    Assignee: ALDERBIO HOLDINGS, LLC
    Inventors: James M. Cregg, Ilya I. Tolstorukov
  • Patent number: 9765352
    Abstract: Compositions and methods are provided for the introduction and the regulated expression of genes in plants. Compositions include promoter constructs that provide a level of activity useful for the regulated expression of site-specific recombinases, while avoiding premature excision. Further provided are isolated polynucleotides encoding novel babyboom polypeptides, expression cassettes, and plants comprising the same. Methods for the introduction of genes into plants are provided, including methods for plastid transformation and methods for the transformation of tissues from mature seeds and leaves.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: September 19, 2017
    Assignees: E I DU PONT DE NEMOURS AND COMPANY, PIONEER HI-BRED INTERNATIONAL, INC.
    Inventors: William James Gordon-Kamm, Theodore Mitchell Klein, Keith S Lowe, Kevin E McBride, Christopher Jay Scelonge, Ning Wang
  • Patent number: 9757379
    Abstract: Provided is a method of inhibiting heterodimerization of HIF-2? to HIF1? (ARNT) comprising binding certain small molecules to the HIF-2? PAS-B domain cavity but not to HIF1? and inhibiting HIF-2? heterodimerization to HIF1? (ARNT) but not inhibiting HIF1? heterodimerization to HIF1? (ARNT). Those certain small molecules are also referenced synonymously as HIF2-HDI and HIF2? heterodimerization inhibitors and also simply as certain small molecules.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: September 12, 2017
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Richard K. Bruick, Charles G. Caldwell, Doug E. Frantz, Kevin H. Gardner, John B. MacMillan, Thomas H. Scheuermann, Uttam K. Tambar
  • Patent number: 9758794
    Abstract: Methods of producing and using Hepatitis C virus (HCV) eE2 polypeptides are described.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: September 12, 2017
    Assignees: Rutgers, The State University of New Jersey, Emory University
    Inventors: Joseph Marcotrigiano, Jillian L. Whidby, Arash Grakoui
  • Patent number: 9750795
    Abstract: Nucleic acid molecules which encode an MRSA PBP2a protein or a fragment thereof which comprises at least 245 amino acid are disclosed. Compositions comprising the nucleic acid molecules are disclosed. Novel proteins which comprise a MRSA PBP2a protein or a fragment thereof which comprises at least 245 amino acid are disclosed are disclosed. Methods of inducing an immune response against MRSA PBP2a are disclosed, as are methods of treating an individual who has been diagnosed with MRSA and methods of preventing MRSA infection in an individual.
    Type: Grant
    Filed: December 11, 2012
    Date of Patent: September 5, 2017
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Matthew P. Morrow
  • Patent number: 9751914
    Abstract: The present invention relates to epitope peptides (or mutants thereof) for treating hepatitis B virus infection, recombinant proteins comprising such epitope peptides (or mutants thereof) and carrier proteins, and uses of such epitope peptides (or mutants thereof) and recombinant proteins. The present invention also relates to antibodies against such epitope peptides, cell lines producing said antibodies, and uses thereof. Furthermore, the present invention relates to vaccines or pharmaceutical compositions for treating or alleviating one or more symptoms associated with hepatitis B virus infection, which comprise the recombinant proteins or antibodies according to the invention, respectively.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: September 5, 2017
    Assignees: Xiamen University, Xiamen Innovax Biotech Co., Ltd.
    Inventors: Quan Yuan, Tianying Zhang, Wenxin Luo, Yixin Chen, Jun Zhang, Ningshao Xia
  • Patent number: 9745378
    Abstract: The present inventors obtained, from a phage library of human antibodies, an anti-mouse NR 10 neutralizing antibody-expressing BM095 clone that shows a strong proliferation-suppressing activity in an IL-31-dependent Ba/F3 cell proliferation assay system. When this anti-mouse NR 10 neutralizing antibody was administered to NC/Nga mice, a model of atopic dermatitis which is a mouse model of chronic dermatitis that arises as a result of repeated applications of picryl chloride, a mouse model of rheumatoid arthritis, and a mouse model of osteoarthritis, a significant effect of symptom suppression was observed. This revealed that the anti-NR 10 neutralizing antibody is indeed effective as a therapeutic agent for inflammatory diseases. In addition, the present inventors successfully obtained an anti-human NR 10 neutralizing antibody, providing extremely useful therapeutic agents with practical clinical applications.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: August 29, 2017
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Masakazu Hasegawa, Hidetomo Kitamura, Hideki Adachi, Keiko Kasutani
  • Patent number: 9738701
    Abstract: The present invention provides combinations of specific binding proteins, such as immunoglobulins, that are designed to be true combinations, essentially all components of the combination being functional and compatible with each other. The invention further provides a method for producing a composition comprising at least two different proteinaceous molecules comprising paired variable regions, the at least two proteinaceous molecules having different binding specificities, comprising paired variable regions, at least two proteinaceous molecules having different binding specificities, comprising contacting at least three different variable regions under conditions allowing for pairing of variable regions and harvesting essentially all proteinaceous molecules having binding specificities resulting from the pairing.
    Type: Grant
    Filed: February 14, 2011
    Date of Patent: August 22, 2017
    Assignee: Merus N.V.
    Inventors: Hendricus Renerus Hoogenboom, Ton Logtenberg
  • Patent number: 9739776
    Abstract: This invention relates to novel rationale and methods for identifying human and primate taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: August 22, 2017
    Assignee: SENOMYX, INC.
    Inventors: Bryan Moyer, Albert Zlotnik, Peter Hevezi, Hortensia Soto, Dalia Kalabat, Min Lu, Na Gao, Evan Carl White
  • Patent number: 9732367
    Abstract: There is provided inter alia a process for stabilizing a eukaryotic cell line which expresses PylRS and tRNAPyl and which is suitable for incorporation of a gene encoding a target protein containing one or more non-natural amino acids encoded by a nonsense codon which comprises culturing said cell line under conditions in which the adverse effect of tRNAPyl expression on cell viability and/or cell growth is reduced or eliminated.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: August 15, 2017
    Assignee: MEDIMMUNE LIMITED
    Inventors: Kenneth H. Grabstein, Michael Van Brunt, Marcello Marelli, William Brady, Jeffrey C. Johnson
  • Patent number: 9732123
    Abstract: Disclosed herein are compositions and methods for treating Clostridium botulinum neurotoxin intoxication and in particular, vaccines against the neurotoxin that provide protection again lethal challenge with neurotoxin from one or more serotypes of Clostridium botulinum.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 15, 2017
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Veronica Scott, Natalie Hutnick
  • Patent number: 9725706
    Abstract: The present invention provides a novel method for the recombinant production of Factor C protein from horseshoe crab using a parasitic protozoan expressing the Factor C protein. In particular, the present invention provides a parasitic protozoan host cell harboring a polynucleotide encoding horseshoe crab Factor C protein, and a method for producing Factor C protein comprising culturing said parasitic protozoan host cell under conditions such that the cells express the horseshoe crab Factor C protein. Furthermore, the present invention provides recombinant Factor C protein produced by the novel method and its use in the detection and/or removal of endotoxin.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: August 8, 2017
    Assignee: HYGLOS INVEST GMBH
    Inventors: Bernd Buchberger, Holger Grallert, Sonja Molinaro
  • Patent number: 9725498
    Abstract: The present disclosure provides synthetic collagen and methods of making and using synthetic collagen that include a synthetic collagen that facilitates wound closure comprising an isolated and purified triple helical backbone protein that facilitates wound closure comprising one or more alteration in a triple helical backbone protein sequence, that stabilize the isolated and purified triple helical backbone protein and does not disrupt an additional collagen ligand interaction; and one or more integrin binding motifs, wherein the isolated and purified triple helical backbone protein facilitates wound closure.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: August 8, 2017
    Assignee: THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Brooke H. Russell, Magnus Hook, Mariah S. Hahn, Elizabeth M. Cosgriff-Hernandez, Neungseon Seo, Marvin Xuejun Xu, Jose J. Rivera, Mary Beth Browning
  • Patent number: 9725725
    Abstract: General methods and strains of bacteria are described that dramatically simplify and streamline plasmid DNA production. In one preferred embodiment, endolysin mediated plasmid extraction combined with flocculation mediated removal of cell debris and host nucleic acids achieves increased yield and purity with simplified downstream purification and reduced waste streams, thus reducing production costs.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: August 8, 2017
    Assignee: Nature Technology Corporation
    Inventors: James A. Williams, Clague P. Hodgson, Aaron E. Carnes
  • Patent number: 9717841
    Abstract: The present invention relates to a method and apparatus for the isolation, modification and re-administration of a molecule or biomolecule, or a class of biomolecules, from the body fluid of a mammal via an extracorporeal closed circuit device. The device is able to capture and modify the biomolecule by the covalent or non-covalent attachment of a secondary molecule or protein, by cross-linking the captured molecule, or by altering the structure of the molecule (for example, by deglycosylation, peptide cleavage, or aggregation). The apparatus can be used to return the modified molecule or biomolecule to the mammalian subject. The device and methods may be utilized for the patient-specific diagnosis and/or treatment of a disease state which presents an associated molecule or protein in plasma or any other fluidized physiological system.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 1, 2017
    Inventor: Gary L. McNeil
  • Patent number: 9708406
    Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: July 18, 2017
    Assignee: GENENTECH, INC.
    Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S. Dennis, James A. Ernst, Ryan J. Watts, Gregory A. Lazar
  • Patent number: 9708379
    Abstract: The present disclosure relates to hemojuvelin-IgG Fc domain fusion proteins, variants, derivatives, fragments and peptide mimetics derived therefrom and methods of using these fusion proteins for the regulation of iron homeostasis and the treatment of diseases related to iron homeostasis.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: July 18, 2017
    Assignees: THE GENERAL HOSPITAL CORPORATION, FERRUMAX CORPORATION
    Inventors: Herbert Y. Lin, Jodie L. Babitt, Tracey Menhall, Patrick Gearing
  • Patent number: 9701713
    Abstract: Disclosed are novel compositions and methods for introduction of macromolecules and nanoparticles into living cells. The invention includes a polypeptide sequence which when fused to a macromolecule or nanoparticle enhances its introduction into the cell.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: July 11, 2017
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Jonathan Mark Petrash, Niklaus Mueller
  • Patent number: 9695403
    Abstract: This invention relates to phytases, polynucleotides encoding them, uses of the polynucleotides and polypeptides of the invention, as well as the production and isolation of such polynucleotides and polypeptides. In particular, the invention provides polypeptides having phytase activity under high temperature conditions, and phytases that retain activity after exposure to high temperatures. The invention further provides phytases which have increased gastric lability. The phytases of the invention can be used in foodstuffs to improve the feeding value of phytate rich ingredients. The phytases of the invention can be formulated as foods or feeds or supplements for either to, e.g., aid in the digestion of phytate.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: July 4, 2017
    Assignee: Syngenta Participations AG
    Inventors: David P. Weiner, Arne I. Solbak, Jr., Ryan McCann
  • Patent number: 9688735
    Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: June 27, 2017
    Assignee: Wyeth LLC
    Inventors: Stephen Berasi, Robert Vincent Martinez, Michael John Cain, John Martin Wozney, Howard Joel Seeherman, Zong Sean Juo, Valerie Perrine Calabro, Christopher Todd Brown
  • Patent number: 9689015
    Abstract: Methods for demannosylating phosphorylated N-glycans on a glycoprotein are described that use a mannosidase capable of hydrolyzing a terminal alpha-1,2 mannose linkage when the underlying mannose is phosphorylated.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: June 27, 2017
    Assignee: Oxyrane UK Limited
    Inventors: Kathleen Camilla Telesphore Alida Maria Piens, Wouter Vervecken
  • Patent number: 9683020
    Abstract: This disclosure relates to immunogenic compositions and methods of enhancing an immune response to an antigen. In certain embodiments, the disclosure relates to virus-like carries comprising a TLR5 agonist on the exterior without an antigen.
    Type: Grant
    Filed: July 31, 2012
    Date of Patent: June 20, 2017
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Richard W. Compans, Baozhong Wang, Fu Shi Quan
  • Patent number: 9683990
    Abstract: The present invention relates to Angiopoietin-3 (Ang-3) and Angiopoietin-4 (Ang-4). The present invention also relates to methods of modulating an activity of Ang-3 or Ang-4. The present invention further relates to methods of treating cancer, diabetes, and arthritis.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: June 20, 2017
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Yin Xu, Qin Yu
  • Patent number: 9683025
    Abstract: The invention provides a peptide construct comprising a cell penetrating peptide and an inhibitory peptide that interferes with the interaction between E1A and CtBP. The invention also provides related pharmaceutical composition comprising such a peptide construct. Also provided is a conjugate comprising such a peptide construct and a carrier molecule. The invention also provides related pharmaceutical compositions. Also provided are related methods of inhibiting cell proliferation in an individual and methods of treating cancer in by such pharmaceutical compositions. The present application also provides methods of treating an inflammatory disease and inhibiting inflammation in an individual comprising administering to the individual an effective amount of a therapeutic agent comprising an inhibitory peptide that interferes with the interaction between E1A and CtBP.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: June 20, 2017
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Qinghong Zhang, Rui Zhao, Xiao-Jing Wang, Melanie Blevins
  • Patent number: 9682098
    Abstract: The invention relates to a compound suited as entity carrier, having the general formula (I) wherein X is an amine-containing residue further defined herein. The invention further relates to the use of such compounds, a nanocarrier system, a kit comprising such compounds and methods for gene silencing and anti-cancer treatment.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: June 20, 2017
    Assignees: Ramot at Tel-Aviv University Ltd., Freie Universitaet Berlin
    Inventors: Rainer Haag, Wiebke Fischer, Abdul Mohiuddin Quadir, Ronit Satchi-Fainaro, Paula Ofek
  • Patent number: 9677079
    Abstract: Disclosed are yeast cells expressing a polypeptide comprising a signal sequence and a human amyloid beta protein. Also disclosed are methods of screening yeast cells to identify compounds that prevent or suppress amyloid beta-induced toxicity and genetic suppressors or enhancers of amyloid beta-induced toxicity. Compounds identified by such screens can be used to treat or prevent neurodegenerative disorders such as Alzheimer's disease.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: June 13, 2017
    Assignee: Whitehead Insititute for Biomedical Research
    Inventors: Kent E. S. Matlack, Susan L. Lindquist, Sebastian Treusch
  • Patent number: 9677104
    Abstract: A process for the production of a target recombinant polypeptide is provided. The process comprises expressing a vector comprising a promoter operatively linked to an expression cassette for the target recombinant polypeptide; and a perfect palindrome operator sequence in a culture medium, wherein the culture medium is substantially free from antibiotic.
    Type: Grant
    Filed: December 10, 2011
    Date of Patent: June 13, 2017
    Assignee: Fujifilm Diosynth Biotechnologies UK Limited
    Inventors: Ian John Hodgson, Tibor Nagy
  • Patent number: 9670519
    Abstract: The present disclosure relates to methods of decreasing lactate production in cell culture using divalent transitional metallic salts. The present disclosure also relates to a method of producing polypeptide by adding divalent transitional metallic salt to the cell culture medium for reducing lactate accumulation followed by fermenting and recovering the polypeptide.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: June 6, 2017
    Assignee: Biocon Limited
    Inventors: Ruchika Srivastava, Sneha Lakshmandas Hemdev, Ankur Bhatnagar, Saravanan Desan, Anuj Goel, Harish Iyer, Vana Raja, Lavanya Rao
  • Patent number: 9670251
    Abstract: The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and/of impairment.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: June 6, 2017
    Assignee: The Arizona Board of Regents on behalf of the University of Arizona
    Inventors: Meredith Hay, John Konhilas, Robin L. Polt, Evan Jones
  • Patent number: 9670474
    Abstract: The present invention provides a fused NHase with improved specific activity and stability, which relates to the field of genetic engineering. This invention provides a method of overexpressing a fused NHase in E. coli and producing a mutant NHase with improved the stability and product tolerance. The invention provides a simple, efficient and safe method of making mutant NHase, and can produce a large amount of soluble NHases in a short period. The present invention makes a contribution to large-scale industrial production and further theoretical study of NHases.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: June 6, 2017
    Assignee: Jiangnan University
    Inventors: Zhemin Zhou, Wenjing Cui, Zhongmei Liu, Li Zhou, Yuanyuan Xia
  • Patent number: 9662378
    Abstract: A vaccine against the Chagas disease, capable of stimulating the immune response against the trans-sialidase virulence factor of the Trypanosoma cruzi parasite, which is a multicomponent vaccine comprising: (a) an immunogenic portion formed by one or more recombinant or synthetic polypeptides or fractions of thereof and (b) one or more polynucleotides including the regions codifying one or more immunogenic polypeptides, or a monocomponent vaccine comprising at least one component selected among an immunogenic portion formed by one or more recombinant or synthetic polypeptides or fractions of them and a group of polynucleotides including the regions codifying one or more immunogenic polypeptides derived from Trypanosoma cruzi and pharmaceutical compositions containing said multicomponent and monocomponent vaccines, the procedures for obtaining the immunogen portion of said vaccines and the nucleic acid used in the procedure.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: May 30, 2017
    Inventor: Carlos de Baeremaecker Barros
  • Patent number: 9657325
    Abstract: Provided is a flavin adenine dinucleotide-dependent glucose dehydrogenase comprising a polypeptide having an amino acid sequence with 78% or more identity to the amino acid sequence of SEQ ID NO: 3, and having glucose dehydrogenase activity.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: May 23, 2017
    Assignee: Toyobo Co., Ltd.
    Inventors: Hiroshi Aiba, Yosuke Sumida, Yasuhiro Yamazaki, Yuu Utashima, Takahide Kishimoto
  • Patent number: 9649361
    Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1?.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: May 16, 2017
    Assignee: Baylor Research Institute
    Inventors: Jacques F. Banchereau, Maria Virginia Pascual
  • Patent number: 9637726
    Abstract: Disclosed are DNA polymerases having increased reverse transcriptase efficiency, mismatch tolerance, extension rate and/or tolerance of RT and polymerase inhibitors relative to a corresponding, unmodified polymerase. The polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the DNA polymerases.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: May 2, 2017
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Keith Bauer, Thomas W. Myers, Fred Reichert, Joseph San Filippo, Rachel Shahinian, Shawn Suko
  • Patent number: 9637751
    Abstract: Polypeptide sequences for inducing recombinant protein bodies are described. The sequences comprise a polyproline II (PPII) structure and/or a proline-rich sequence between two cysteine residues on either end. Recombinant protein bodies are useful for protein production because they allow for simple and efficient purification of high quantities of recombinant protein. In addition, other methods of using recombinant protein bodies, for example, in vaccination and food products, are also described.
    Type: Grant
    Filed: May 31, 2011
    Date of Patent: May 2, 2017
    Assignee: ERA BIOTECH, S.A.
    Inventors: Maria Dolores Ludevid Múgica, Maria Immaculada Llop Tous, Pablo Marzábal Luna, Minu Joseph, Blanca Llompart Royo, Margarita Torrent Quetglas, Miriam Bastida Virgili
  • Patent number: 9637734
    Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: May 2, 2017
    Assignee: BioAtla, LLC
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Patent number: 9631197
    Abstract: The invention relates to a method for carrying out recombination at a target locus in a Rasamsonia cell. The invention also relates to Rasamsonia cells, for example Rasamsonia cells produced by such a process. The invention further relates to processes in which such Rasamsonia cells are used and to the resulting enzyme compositions. The invention further relates to nucleic acid and amino acid sequences.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: April 25, 2017
    Assignee: DSM IP ASSETS B.V.
    Inventors: Alrik Pieter Los, Yvonne Johannes Odilia Arendsen, Adrianus Wilhelmus Hermanus Vollebregt
  • Patent number: 9630997
    Abstract: Disclosed are compositions and methods for expressing and purifying a peptide of interest using a Flagellar Type III secretion system. Disclosed are nucleic acid sequences that contain a FlgM nucleic acid sequence, a cleavage site, and a nucleic acid sequence of interest. Also disclosed are polypeptides that contain FlgM, a cleavage site and a peptide of interest. Methods of producing polypeptides that have FlgM, a cleavage site and a peptide of interest are provided.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: April 25, 2017
    Assignee: University of Utah Research Foundation
    Inventors: Kelly T. Hughes, Baldomero M. Olivera
  • Patent number: 9624481
    Abstract: Provided are isolated polypeptides having beta-xylosidase activity and polynucleotides encoding the polypeptides. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: April 18, 2017
    Assignee: Novozymes, Inc.
    Inventors: Ye Liu, Lan Tang, Yu Zhang, Junxin Duan
  • Patent number: 9624286
    Abstract: Provided is a pharmaceutical or cosmetic composition comprising adiponectin-derived peptide fragments, i.e., the peptides of SEQ ID NOs: 1 to 6 as an active ingredient. The peptides facilitate skin regeneration and moisturization, inhibit skin wrinkle, and have inhibitory activities against allergy and inflammation as well as metastasis of cancer cells.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: April 18, 2017
    Assignees: KNU-INDUSTRY COOPERATION FOUNDATION, SUPADELIXIR INC.
    Inventors: Jang-Hee Hahn, Dong-Young Lim
  • Patent number: 9617335
    Abstract: The present invention is an inducible coexpression system, capable of controlled induction of expression of each gene product.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: April 11, 2017
    Assignee: AbSci LLC
    Inventors: Sean McClain, Mark Valasek
  • Patent number: 9617525
    Abstract: The instant invention provides methods and related compositions for identifying polypeptides with improved stability and/or enzymatic activity in comparison to native forms, wherein the identified polypeptides comprise one or more non-natural amino acids. In certain embodiments, the present invention relates to novel phosphotriesterase enzymes comprising one or more non-natural amino acids. In a particular embodiment, the instant invention provides novel phosphotriesterase enzymes with greater stability and/or enhanced activity in comparison to native forms of the enzyme. The present invention also relates to compositions comprising novel phophotriesterase enzymes, such as prophylactics, decontaminants, animal feedstocks, and assay kits.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: April 11, 2017
    Assignee: New York University
    Inventors: Jin Kim Montclare, Richard Bonneau, P. Douglas Renfrew, Ching-Yao Yang, Carlo Yuvienco
  • Patent number: 9617523
    Abstract: The present invention relates to a host organism containing recombinant nucleic acids coding for the vitamin K reductase complex subunit 1 (VKORC1) and recombinant nucleic acids coding for a vitamin K dependent (VKD) protein, wherein both the recombinant VKORC1 and the recombinant VKD protein are expressed in said host organism. Further, the present invention relates to a cell culture system comprising cells which contain said recombinant nucleic acids and to methods for improving the productivity of recombinant VKD protein expression in a host organism being cultured in suitable systems.
    Type: Grant
    Filed: January 27, 2006
    Date of Patent: April 11, 2017
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Friedrich Scheiflinger, Ernst Boehm
  • Patent number: 9611462
    Abstract: The present invention provides endoglucanase 1b (EG1b) variants suitable for use in saccharification reactions. The present application further provides genetically modified fungal organisms that produce EG1b variants, as well as enzyme mixtures exhibiting enhanced hydrolysis of cellulosic material to fermentable sugars, enzyme mixtures produced by the genetically modified fungal organisms, and methods for producing fermentable sugars from cellulose using such enzyme mixtures.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: April 4, 2017
    Assignee: Codexis, Inc.
    Inventors: Ee Lui Ang, Ellen D. Eberhard, Xiyun Zhang, Wei Zhang, Jing Tian, Derek J. Smith, Vesna Mitchell
  • Patent number: 9603907
    Abstract: DNase I formulations for pulmonary administration and, more particularly, but not exclusively, a dry powder formulation comprising, as an active ingredient, human DNase I, methods, dry powder inhalation devices and systems for the therapeutic use thereof are provided.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: March 28, 2017
    Assignee: Protalix Ltd.
    Inventors: Yoseph Shaaltiel, Uri Hanania, Tali Kizhner, Yulia Matiuhin, Liat Fux, Avidor Shulman
  • Patent number: 9603906
    Abstract: An inhalable pharmaceutical composition for pulmonary administration comprising human DNase I and a liquid carrier and, more particularly, but not exclusively, to methods, liquid pharmaceutical inhalation devices and systems for the therapeutic use thereof are provided.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: March 28, 2017
    Assignee: Protalix Ltd.
    Inventors: Yoseph Shaaltiel, Uri Hanania, Tali Kizhner, Yulia Matiuhin, Liat Fux, Avidor Shulman
  • Patent number: 9605039
    Abstract: Disclosed herein are proteins that include an immunoglobulin fold and that can be used as scaffolds. Also disclosed herein are nucleic acids encoding such proteins and the use of such proteins in diagnostic methods and in methods for evolving novel compound-binding species and their ligands.
    Type: Grant
    Filed: October 3, 2006
    Date of Patent: March 28, 2017
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Dasa Lipovsek, Richard W. Wagner, Robert G. Kuimelis
  • Patent number: 9605045
    Abstract: A plastid transformation vector for stably transforming a plastid genome, comprising, as operably-linked components, a first flanking sequence, a DNA sequence coding for synthetic insulin-like growth factor-1 (IGF-1s) (SEQ ID NO. 1) or a substantially homologous DNA sequence of IGF-1s, which is capable of expression in the plastid genome, and a second flanking sequence.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: March 28, 2017
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Henry Daniell
  • Patent number: 9598710
    Abstract: The invention provides an isolated genetically modified non-mammalian organism, wherein the activity of acyl-CoA:sterol acyltransferase/sterol O-acyltransferase (EC 2.3.1.26) and/or diacylglycerol acyltransferase/diacylglycerol O-acyltranferase (EC 2.3.1.20) and/or lecithin cholesterol acyl transferase/phospholipid:diacylglycerol acyltransferase (EC 2.3.1.158) and/or acyl CoA-wax alcohol acyltransferase (EC 2.3.1.75) is reduced or abolished in comparison with a corresponding wildtype organism, methods of use of such an organism, shuttle vehicles for making such an organism and methods for producing such an organism.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: March 21, 2017
    Assignee: ORGANOBALANCE GMBH
    Inventors: Christine Lang, Andreas Raab
  • Patent number: 9592285
    Abstract: An aspect of the present invention is directed towards DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of influenza virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient. The DNA plasmid is capable of expressing a consensus influenza antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal, wherein the consensus influenza antigen comprises consensus hemagglutinin (HA), neuraminidase (NA), matrix protein, nucleoprotein, M2 ectodomain-nucleo-protein (M2e-NP), or a combination thereof. Preferably the consensus influenza antigen comprises HA, NA, M2e-NP, or a combination thereof. The DNA plasmid comprises a promoter operably linked to a coding sequence that encodes the consensus influenza antigen. Additionally, an aspect of the present invention includes methods of eliciting an immune response against a plurality of influenza virus subtypes in a mammal using the DNA plasmid vaccines provided.
    Type: Grant
    Filed: November 12, 2008
    Date of Patent: March 14, 2017
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Ruxandra Draghia-Akli, David B. Weiner, Jian Yan, Dominick Laddy